Io Biotech Stock Current Valuation
| IOBT Stock | USD 0.75 0.04 5.63% |
Valuation analysis of IO Biotech helps investors to measure IO Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, IO Biotech's Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.68 in 2024, despite the fact that Enterprise Value is likely to grow to (80.3 M). Fundamental drivers impacting IO Biotech's valuation include:
Price Book 0.6809 | Enterprise Value -28.8 M | Enterprise Value Ebitda 1.3637 |
Undervalued
Today
Please note that IO Biotech's price fluctuation is dangerous at this time. Calculation of the real value of IO Biotech is based on 3 months time horizon. Increasing IO Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
IO Biotech's intrinsic value may or may not be the same as its current market price of 0.75, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.75 | Real 3.06 | Target 10.0 | Hype 0.77 |
The intrinsic value of IO Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IO Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of IO Biotech helps investors to forecast how IOBT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IO Biotech more accurately as focusing exclusively on IO Biotech's fundamentals will not take into account other important factors: IO Biotech Company Current Valuation Analysis
IO Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current IO Biotech Current Valuation | (28.76 M) |
Most of IO Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IO Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IOBT Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Current Valuation. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, IO Biotech has a Current Valuation of (28.76 Million). This is 100.2% lower than that of the Biotechnology sector and 100.62% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.17% higher than that of the company.
IOBT Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.IO Biotech is currently under evaluation in current valuation category among its peers.
IOBT Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | (28.76 M) | ||||
| Shares Outstanding | 65.88 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 76.79 % | ||||
| Number Of Shares Shorted | 200.92 K | ||||
| Price To Book | 0.68 X | ||||
| EBITDA | (91.23 M) | ||||
| Net Income | (86.08 M) | ||||
| Cash And Equivalents | 170.12 M | ||||
| Cash Per Share | 5.90 X | ||||
| Total Debt | 2.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 20.94 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (71.74 M) | ||||
| Short Ratio | 1.89 X | ||||
| Earnings Per Share | (1.29) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 74 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 49.41 M | ||||
| Total Asset | 150.72 M | ||||
| Retained Earnings | (263.82 M) | ||||
| Working Capital | 131.54 M | ||||
| Net Asset | 150.72 M |
About IO Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.